Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALBO · as of Jun 9, 2026
Key Statistics
Explore Albireo Pharma, Inc. Data
albo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 12 · Buy rate: 58.3%
The ALBO analyst consensus is Buy, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month price target is $44.00, representing -0.34% downside from the current price of $44.15.
Competitors & Peers
albo competitorsALBO
CBIO
CDMO
CMRX
GRCL
HARPStock Performance
Full HistoryAbout Albireo Pharma, Inc.
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targe…
what is albireo pharma, inc. · albo stock overview · albireo pharma, inc. company profile · who is albireo pharma, inc. ceo · albo NASDAQ · albireo pharma, inc. headquarters · albireo pharma, inc. business segments
About Stock Overview & Key Data
Albireo Pharma, Inc. (ALBO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 11, 2007. As of the latest trading session, ALBO stock price is $44.15, with a market capitalization of $915.9M. The stock has returned +42.88% over the past 12 months and +106.60% year-to-date.
According to 12 Wall Street analysts, the consensus rating for Albireo Pharma, Inc. stock is Buy, with an average 12-month price target of $44.00. In fiscal year 2021, Albireo Pharma, Inc. reported revenue of $40.6M and net income of -$151.3M. For detailed data — including Albireo Pharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Albireo Pharma, Inc. (ALBO) stock price is $44.15. The stock is traded on NASDAQ under the ticker symbol ALBO. The 52-week range is $16.02 – $45.23.